# Subject index of Volume 125 · 1996


Abuse liability 1
Acetylcholine 162
Addiction 285
Additive summation 202
Adenylate cyclase 185
Adrenalectomy 265
Aging 50
Alcohol 248, 285, 398
Alcohol drinking 57
Alcohol intake 398
Alcohol self-administration 398
Alternative nondrug reinforcer 355
Ambulatory activity 129
AMPA (α-amino-3-hydroxy-4-isoxazole propionicacid) lesions 146
Amphetamine 43, 92, 285
Amygdala 285
Angiotensin II 57
Animal models of dependence 285
Anorexia 168
Antidepressants 274
Antipsychotic drug 105
Anxiety 141, 392
Arousal 79
Atypical neuroleptic 105
Aversion 92
Baboon 120
Balanced placebo design 371
Behavior 220
Behavioral economics 105, 195, 355
Behavioral sensitization 33
Behavioural genetics 285
Benzodiazepine 179
Benzodiazepines 392
Biological markers of dependence 285
Brain 398
Brain metabolism 214
Buprenorphine 355
Butorphanol 135
$Ca^{2+}$ channel 135
Cerebral cortex 285
Ceruletide 185
Cheating 255
Chronic fluphenazine 185
Circular maze 23
Clocinnamox 113
Cocaine 13, 33, 97, 120, 202, 285, 346, 355, 361, 379
Cocaine base 195
Cognition 50, 179
Co-morbidity 285
Compliance 255
Conditioned place preference 209
Conditioned taste aversion 43
Confound 255
Cortex 162
Corticosterone 265
Crack 195
Craving 285
Cross-sensitization 33
Cytochrome P-450 214
Cytosol 214
$D_1$ agonist 97
$D_1$ receptor 185
$D_2$ agonist 97
*d*-Amphetamine 371
Dependence 285, 379
Depression 74, 141, 285
Desipramine 274
*d*-Fenfluramine 168
Diazepam 392
Diltiazem 135
Discriminative effects 285
Dizocilpine 23, 209
Dopamine 97, 105, 135, 265, 285, 385
Dopamine $D_1$ receptors 162
Dopamine $D_2$-type receptors 33
Dopamine $D_3$ receptors 33
Dopamine receptors 13
Dorsal raphe nucleus 89
Drug abuse 285, 346
Drug discrimination 113, 220, 255
Drug metabolism 214
Drug self-administration 195
Drug tolerance 220
Drugs of abuse 92
EEG 179
Epidemiology of dependence 285
ERP 179
Estradiol 141
Estrogen 65
Ethanol 23, 258
Ethanol intake 398
Ethanol self-administration 398
Excitation 258
Expectancy 371
Experimental history 13
Fawn-hooded rats 74
Feeding 79
Female 346
Fixed-interval peak procedure 274
Fixed-ratio 97, 355
Flunitrazepam 1
$^3$H-flunitrazepam binding 65
Fluvoxamine 274
Footshock 43
Forced swimming test 74
Forebrain cholinergic projection system 146
Functional neuroimaging 285
$GABA_A$ receptor 65
Gender differences 346
Genetic differences 248
Glucose+saccharin 355
Glutamate synapses 238
GnRH agonist 141
Gonadotropin 141
Guinea pig 231
Habit 285
Hallucinogens 285
Haloperidol 214, 238
Heroin 195, 248, 385
Holeboard 74
HPLC-ED 135
$HPP^+$ Haloperidol pyridinium derivative 214
5-HT 285
5-HT1B 231
5-HT1D 231
$5\text{-}HT_3$ receptor antagonists 146
Human 371
Human subjects 346
Human tissue 214
Humans 176, 255
Hypnotics 179
Incentive learning 79
Incentive-motivation 202
Individual differences 92, 285
Individual variability 258
Inhalation 195
Instrumental conditioning 79
Interval bisection task 274
Intravenous 355
Intravenous drug self-administration 248, 385
Ketone reductases 214
Learning 23, 220
Lever release 120
Lithium 162
Locomotor activity 33, 231
Loperamide 195
Male 346
Mania 162
Memory 50
Metergoline 168
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 214
Methylphenidate 162
Microdialysis 162
Mitochondria 214
MK-801 209
Morphine 92, 113, 129, 135, 209, 220
Motivation 105
Mouse 129
Movement 105
Nalbuphine 113
Naloxone 92, 129
Naloxone antagonism 195
Naltrexone 113
Neural systems 285
Neurosteroids 65
Neurotensin 57
Neurotoxin 214
Nicotine 176, 285
Nitric oxide 398
NMDA 209
NMDA receptor 23
Nucleus accumbens 285
7-OH-DPAT 13, 33
8-OH-DPAT 79, 89, 168
Operant 105
Opiates 285
Opioid dependence 135
Opioid drugs 385
Opponent process theories 285
Oral route 379
P300 179
$pA_2$ analysis 113
Perforated postsynaptic density 238
Performance 1
Personality and dependence 285
PET 285
Pharmacological treatment for dependence 285
(+)-PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] 97
Pituitary-adrenal axis 74

Place avoidance 92
Place preference 92
Placebo 392
Plasma levels 346
Platelets 141
Plus-maze 65, 74
Post-morphine treatment 129
Prepulse inhibition 231
Progesterone 65, 141
Progressive-ratio 361
Psychomotor stimulants 285
Psychosocial treatment of dependence 285
Psychostimulants 265
Quantitative trait loci 285
Quinine 255
Quinpirole 97
Rat 79, 89, 168, 202, 231, 274
Rats 220, 258, 355
Reaction time procedure 120
Reduced haloperidol 214
Reinforcement 105, 209, 285, 361
Reinforcing efficacy 361
Reinstatement 385
Relapse 285, 385
Renin-angiotensin system 57
Repeated administration 129
Restraint 129
Reward 92, 209
Rhesus monkey 13, 361
Rhesus monkeys 195
RHPP+ reduced haloperidol pyridinium derivative 214
Risk factors 285
Saccharin 43
Satiety sequence 168
Schizophrenia 285
Scopolamine 50
Second-order 97
Sedation 105, 258
Selected rat lines 248
Self-administration 13, 97, 202, 355, 361, 371, 379
Sensitization 129, 285
Serotonin 79, 231
Serotonin transporter 141
SKF 77434 [*R,S*-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine] 97
SKF 81297 [*R,S*-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine] 97
SKF 82958 [*R,S*-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine] 97
Sleepiness 179
Smoking 195
Smoking style 176
Sociology of dependence 285
Somatodendritic 5-$HT_{1A}$ receptors 89
Spatial learning and memory 146
Speech sounds 120
Squirrel monkey 97
Startle 231
Stimulus control 120, 202
Strain-dependent effects 285
Stress 43, 65, 74, 385
Striatum 238, 285
Subject ratings 1
Subjective 285
Subjective effects 346, 371
Tactile startle reflex 379
Tardive dyskinesia 185, 238
Tasting 255
Timing 274
Tolerance 23, 113, 258, 285
Transcription factors 285
Triazolam 1
Ultrasound 379
Vacuous chewing movements 238
Vocalizations 379
Vowels 120
Water maze 146
WAY-100635 89, 168
Withdrawal 285, 379
Withdrawal symptoms 392